narcan naloxone hci spray
hf acquisition co llc, dba healthfirst - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. 8.1 pregnancy risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations]. in animal reproduction studies, no embryotoxic or
narcan
phebra pty ltd - naloxone hydrochloride -
narcan- naloxone hydrochloride spray
lake erie medical dba quality care products llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 4 mg in 0.1 ml - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations ]. in animal reproduction studies, no embryotoxic or teratogenic effects were observed in mice and rats treated with naloxone hydrochloride during the period of organogenesis at doses equivalent to 6-times and 12-times, respectively, a human dose of 8 mg/day (two narcan nasal sprays) based on body surface area comparison [se
nubain injection 20mg/ml solution
sandoz canada incorporated - nalbuphine hydrochloride - solution - 20mg - nalbuphine hydrochloride 20mg - opiate partial agonists
benefix
wyeth farma s.a. - nonacog alfa - powder for solution for injection - 250iu
benefix
wyeth farma s.a. - nonacog alfa - powder for solution for injection - 500iu
benefix
wyeth farma s.a. - nonacog alfa - powder for solution for injection - 1000iu
narcan injection 0.4mg/ml solution
bristol-myers squibb canada - naloxone hydrochloride - solution - 0.4mg - naloxone hydrochloride 0.4mg - opiate antagonists
narcan neo-natal injection 0.02 mg/ml
wael pharmacy - naloxone hydrochloride - injection - 0.02
narcan injection 0.4 mg/ml
wael pharmacy - naloxone hydrochloride - injection - 0.4